This work establishes how 3D epigenomic reprogramming cooperates with redox adaptation to drive HB pathogenesis, positioning the TCF3-TRIB2-NRF2 axis as a promising biomarker and therapeutic target in HB. The gene discussed is NFE2L2; the disease is hemoglobin measurement.